This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tranche Update on Chongqing Zhifei Biological Products Co., Ltd.'s Equity Buyback Plan announced on February 22, 2024. CI
Chongqing Zhifei Biological Products Co., Ltd.'s Equity Buyback announced on February 22, 2024, has closed with 6,210,253 shares, for CNY 300.01 million. CI
Chongqing Zhifei Biological Products Co., Ltd. announces an Equity Buyback for CNY 500 million worth of its shares. CI
Chongqing Zhifei Biological Products Co., Ltd. authorizes a Buyback Plan. CI
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China MT
Zhifei Biological Products to Acquire Local Biopharma Firm, Expanding Into Metabolic Disease Treatments MT
Chongqing Zhifei Biological Products Co., Ltd. signed a letter of intent to acquire Shanghai Polaris Biology Co., Ltd. CI
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Middle East Conflict Weighs on Exchange-Traded Funds, Equity Futures Pre-Bell Monday MT
GSK Signs Distribution Deal With China's Zhifei for Shingles Vaccine MT
Chongqing Zhifei Biological Enters Exclusive Distribution Deal With GSK MT
Trending : GSK Signs $3 Billion Shingles Vaccine Deal in China DJ
GSK Strikes $3.06 Billion Shingles Vaccine Deal With China's Zhifei -- Update DJ
European Midday Briefing : Oil Surges, Stocks Fall on Middle East Conflict DJ
GSK inks agreement with Zhifei to promote shingles vaccine AN
GSK Secures GBP2.5 Billion Partnership for Shingles Vaccine in China MT
GSK signs shingles vaccine deal with China's Zhifei for about $3 bln RE
Metro Bank secures deal to shore up finances AN
GSK Partners With Zhifei to Boost Shingles Vaccine Availability in China DJ
GSK signs shingles vaccine deal with China's Zhifei for about $3 bln RE
GSK plc and Zhifei Announce Exclusive Strategic Vaccine Partnership in China CI
Zhifei Biological Products’ H1 Profit Rises 14% as Revenue Jumps 33% MT
Chongqing Zhifei Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
EVE Energy Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 16 June 2023 CI
Chongqing Zhifei Biological Products Co., Ltd Approves the Cash Dividend for 2022 CI
Chart Chongqing Zhifei Biological Products Co., Ltd.
More charts
Chongqing Zhifei Biological Products Co., Ltd. specializes in the research and development of vaccines for human use. The products include, in particular, bacterial vaccines for the prevention of meningitis, tuberculosis, rabies and influenza.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
40.49 CNY
Average target price
71.15 CNY
Spread / Average Target
+75.73%
Consensus
  1. Stock Market
  2. Equities
  3. 300122 Stock
  4. News Chongqing Zhifei Biological Products Co., Ltd.
  5. Zhifei Biological Wins Nod to Sell COVID-19 Vaccine in China; Shares Rise 3%